UNLABELLED: This was a first-in-human study of the novel phosphodiesterase-2A (PDE2A) PET ligand (18)F-PF-05270430. The primary goals were to determine the appropriate tracer kinetic model to quantify brain uptake and to examine the within-subject test-retest variability. METHODS: In advance of human studies, radiation dosimetry was determined in nonhuman primates. Six healthy male subjects participated in a test-retest protocol with dynamic scans and metabolite-corrected input functions. Nine brain regions of interest were studied, including the striatum, white matter, neocortical regions, and cerebellum. Multiple modeling methods were applied to calculate volume of distribution (VT) and binding potentials relative to the nondisplaceable tracer in tissue (BPND), concentration of tracer in plasma (BPP), and free tracer in tissue (BPF). The cerebellum was selected as a reference region to calculate binding potentials. RESULTS: The dosimetry study provided an effective dose of less than 0.30 mSv/MBq, with the gallbladder as the critical organ; the human target dose was 185 MBq. There were no adverse events or clinically detectable pharmacologic effects reported. Tracer uptake was highest in the striatum, followed by neocortical regions and white matter, and lowest in the cerebellum. Regional time-activity curves were well fit by multilinear analysis-1, and a 70-min scan duration was sufficient to quantify VT and the binding potentials. BPND, with mean values ranging from 0.3 to 0.8, showed the best intrasubject and intersubject variability and reliability. Test-retest variability in the whole brain (excluding the cerebellum) of VT, BPND, and BPP were 8%, 16%, and 17%, respectively. CONCLUSION: (18)F-PF-05270430 shows promise as a PDE2A PET ligand, albeit with low binding potential values.
UNLABELLED: This was a first-in-human study of the novel phosphodiesterase-2A (PDE2A) PET ligand (18)F-PF-05270430. The primary goals were to determine the appropriate tracer kinetic model to quantify brain uptake and to examine the within-subject test-retest variability. METHODS: In advance of human studies, radiation dosimetry was determined in nonhuman primates. Six healthy male subjects participated in a test-retest protocol with dynamic scans and metabolite-corrected input functions. Nine brain regions of interest were studied, including the striatum, white matter, neocortical regions, and cerebellum. Multiple modeling methods were applied to calculate volume of distribution (VT) and binding potentials relative to the nondisplaceable tracer in tissue (BPND), concentration of tracer in plasma (BPP), and free tracer in tissue (BPF). The cerebellum was selected as a reference region to calculate binding potentials. RESULTS: The dosimetry study provided an effective dose of less than 0.30 mSv/MBq, with the gallbladder as the critical organ; the human target dose was 185 MBq. There were no adverse events or clinically detectable pharmacologic effects reported. Tracer uptake was highest in the striatum, followed by neocortical regions and white matter, and lowest in the cerebellum. Regional time-activity curves were well fit by multilinear analysis-1, and a 70-min scan duration was sufficient to quantify VT and the binding potentials. BPND, with mean values ranging from 0.3 to 0.8, showed the best intrasubject and intersubject variability and reliability. Test-retest variability in the whole brain (excluding the cerebellum) of VT, BPND, and BPP were 8%, 16%, and 17%, respectively. CONCLUSION: (18)F-PF-05270430 shows promise as a PDE2A PET ligand, albeit with low binding potential values.
Authors: Paul Morgan; Piet H Van Der Graaf; John Arrowsmith; Doug E Feltner; Kira S Drummond; Craig D Wegner; Steve D A Street Journal: Drug Discov Today Date: 2011-12-29 Impact factor: 7.851
Authors: Donald H Maurice; Hengming Ke; Faiyaz Ahmad; Yousheng Wang; Jay Chung; Vincent C Manganiello Journal: Nat Rev Drug Discov Date: 2014-04 Impact factor: 84.694
Authors: Lei Zhang; Anabella Villalobos; Elizabeth M Beck; Thomas Bocan; Thomas A Chappie; Laigao Chen; Sarah Grimwood; Steven D Heck; Christopher J Helal; Xinjun Hou; John M Humphrey; Jiemin Lu; Marc B Skaddan; Timothy J McCarthy; Patrick R Verhoest; Travis T Wager; Kenneth Zasadny Journal: J Med Chem Date: 2013-05-28 Impact factor: 7.446
Authors: Frederik J R Rombouts; Gary Tresadern; Peter Buijnsters; Xavier Langlois; Fulgencio Tovar; Thomas B Steinbrecher; Greet Vanhoof; Marijke Somers; José-Ignacio Andrés; Andrés A Trabanco Journal: ACS Med Chem Lett Date: 2015-01-15 Impact factor: 4.345
Authors: D T Stephenson; T M Coskran; M P Kelly; R J Kleiman; D Morton; S M O'Neill; C J Schmidt; R J Weinberg; F S Menniti Journal: Neuroscience Date: 2012-09-19 Impact factor: 3.590
Authors: Jean-Dominique Gallezot; Ming-Qiang Zheng; Keunpoong Lim; Shu-fei Lin; David Labaree; David Matuskey; Yiyun Huang; Yu-Shin Ding; Richard E Carson; Robert T Malison Journal: J Nucl Med Date: 2014-04-14 Impact factor: 10.057
Authors: Laigao Chen; Nabeel Nabulsi; Mika Naganawa; Kenneth Zasadny; Marc B Skaddan; Lei Zhang; Soheila Najafzadeh; Shu-Fei Lin; Christopher J Helal; Tracey L Boyden; Cheng Chang; Jim Ropchan; Richard E Carson; Anabella Villalobos; Yiyun Huang Journal: J Nucl Med Date: 2016-05-19 Impact factor: 10.057
Authors: Reagan Farmer; Steven D Burbano; Neema S Patel; Angelo Sarmiento; Abigail J Smith; Michy P Kelly Journal: Cell Signal Date: 2020-02-29 Impact factor: 4.315
Authors: Sagnik Bhattacharyya; Alice Egerton; Euitae Kim; Lula Rosso; Daniela Riano Barros; Alexander Hammers; Michael Brammer; Federico E Turkheimer; Oliver D Howes; Philip McGuire Journal: Sci Rep Date: 2017-11-03 Impact factor: 4.379
Authors: Stuart P McCluskey; Christophe Plisson; Eugenii A Rabiner; Oliver Howes Journal: Eur J Nucl Med Mol Imaging Date: 2019-09-21 Impact factor: 9.236